Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
The Pharma Data
DECEMBER 21, 2020
The collaboration combines Sosei Heptares’ structure-based drug design (SBDD) platform, including its structural insights around the target, and its deep understanding of GPCR pharmacology, together with Captor’s proprietary TPD Optigradeä, platform and extensive know-how and expertise in protein degradation.
40 
Let's personalize your content